Table 1.
Clinical information of the COVID-19 group.
| Patient code | Maternal age (yr) | Maternal Comorbidities | COVID-19 Symptoms/Severe Disease | SARS-CoV-2 testing | Outcome | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| RT-PCR Maternal NS swab/Trimester | Maternal Serology | RT-PCR placenta/RT-PCR fetal samples | Gestational age at delivery | APGAR (1 min/5 min)/Fetal-Maternal Outcome | Fetal weight (g) | Placental weight (g)/Macroscopic alterations | ||||
| 20–3594 | 26 | Hypertensive disorder in pregnancy and hypothyroidism | +/+ | +/3rd | IgM+/IgG+ | −/− | 33 | (5/9) Preterm newborn | 2450 | 448/Infarcts (<5%) |
| 20–3561 | 38 | Hypothyroidism | +/+ | */2nd | IgM+/IgG+ | −/− | 28+2 | (na) Preterm newborn | na | 245 |
| 20–3282 | 40 | Situs inversus totalis with metallic stent | +/+ | +/3rd | na | −/+** | 33+5 | (0/0) Neonatal death/Maternal death | 2300 | 416 |
| 20–5379 | 38 | Gestational diabetes | +/+ | +/2nd | na | −/+** | 23+6 | (1/5) Neonatal death/Maternal death | 610 | 168/Placental hypoplasia |
| 20–3744 | 29 | Gestational diabetes, hypothyroidism, obesity, bipolar disorder, and syphilis (treated) | +/− | +/3rd | IgM+/IgG+ | −/+** | 34+1 | (na) Preterm newborn | na | 412/Infarcts (<5%) |
| 20–5105 | 29 | None | − | +/3rd | na | −/na | 38+6 | (9/10) Term newborn | 2960 | 462 |
| 20–3369 | 29 | Gestational diabetes and Hyperthyroidism | +/− | +/3rd | na | −/na | 37+4 | (8/9) Term newborn | 2600 | 358/Infarcts (<5%) |
| 20–3364 | 42 | Hypertensive disorder in pregnancy | +/+ | +/2nd | IgM+/IgG+ | +/+§ | 28+3 | Intrauterine death | 1020 | 135/Placental hypoplasia and infarcts (30–40%) |
| 20–5776 | 42 | None | − | +/3rd | na | −/+** | 36+5 | (9/10) Preterm newborn | 2605 | 382 |
| 20–5869 | 27 | None | +/− | +/3rd | na | −/na | 37+2 | (9/10) Term newborn | 2345 | 370 |
| 20–3916 | 24 | None | − | +/3rd | IgM+/IgG+ | −/na | 38+6 | (9/10) Term newborn | 3030 | 650 |
| 20–4850 | 25 | Obesity | +/+ | +/3rd | na | na/− | 30+2 | (na) Preterm newborn | na | 410 |
| 20–5006 | 22 | Obesity | − | +/3rd | na | na/− | 41+0 | (4/9) Term newborn | 3110 | 670 |
| 20–5009 | 23 | Hypothyroidism | − | */3rd | IgM+/IgG+ | na/− | 38+4 | (5/9) Term newborn | 3925 | 775/Hydropic placenta |
| 20–5031 | 35 | Gestational diabetes, obesity | − | +/3rd | na | na/− | 36+4 | (8/9) Preterm newborn | 2720 | 450 |
| 20–6551 | 32 | None | − | +/3rd | na | na/na | 38+5 | (8/9) Term newborn | 3070 | 448 |
| 20–6680 | 38 | None | − | +/3rd | na | na/na | 37 | (9/10) Term newborn | 2875 | 318 |
| 20–7035 | 34 | None | − | +/3rd | na | na/− | 39 | (9/9) Term newborn | 3115 | 438 |
| 20–6071 | 34 | Hypertensive disorder in pregnancy | − | +/3rd | na | na/− | 34+6 | (7/8) Preterm newborn | 2370 | 384 |
*rt-PCR not available—diagnostic by serology.
RT-PCR positive in fetal samples: **Nasofaringeal swab and §Umbilical cord blood.
na, not available.